Abstract
In their letter, Drs Smolderen and Pelle correctly point out that patients with cardiovascular disease (CVD) have a high rate of comorbid depression, that depressed patients have less success when they attempt to stop smoking, and that the exclusion of smokers with comorbid depression from our trial of varenicline in patients with CVD limits our ability to generalize the results of our study to all smokers with CVD, as we had noted in the original article.1 As they request, we clarify here why our trial excluded CVD patients with comorbid depression. According to standard methodology used in testing new drugs, medications not specifically intended for psychiatric indications are …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
